{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:51Z","timestamp":1786998471798,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ymgme.2019.12.010","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T17:54:04Z","timestamp":1576691644000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients"],"prefix":"10.1016","volume":"129","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.12.010_bb0005","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0010","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: Lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0025","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS\/MS in urine of Fabry disease patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0045","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group: safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0070","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ckj\/sfw082","article-title":"FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease","volume":"9","author":"Mignani","year":"2016","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.ymgme.2019.12.010_bb0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ckj\/sfy108","article-title":"New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases","author":"Mignani","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ckj\/sfy126","article-title":"Will the FAbry STabilization indEX make its way to everyday clinical practice?","volume":"12","author":"Cairns","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and switch \u22122-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0100","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (chronic kidney disease epidemiology collaboration): a new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0120","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"141","author":"Lenders","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0130","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and later-onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Gen. Metab."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/8904_2015_483","article-title":"Reduction of plasma Globotriaosylsphingosine levels after switching from Agalsidase Alfa to Agalsidase Beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Reports"},{"key":"10.1016\/j.ymgme.2019.12.010_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0160","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.12.010_bb0165","doi-asserted-by":"crossref","first-page":"15277","DOI":"10.1038\/s41598-019-51805-6","article-title":"Circulating microRNAs in Fabry disease","volume":"9","author":"Xiao","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219306973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219306973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:24:21Z","timestamp":1761089061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219306973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1096719219306973"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.12.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}